Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.18
GSK's Cash to Debt is ranked lower than
56% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. GSK: 0.18 )
GSK' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.18

Equity to Asset 0.16
GSK's Equity to Asset is ranked lower than
56% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. GSK: 0.16 )
GSK' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.16

0.05
0.4
Interest Coverage 9.68
GSK's Interest Coverage is ranked higher than
53% of the 449 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 124.75 vs. GSK: 9.68 )
GSK' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 7
Z-Score: 2.35
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 26.52
GSK's Operating margin (%) is ranked higher than
94% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. GSK: 26.52 )
GSK' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 26.52

1.68
36.94
Net-margin (%) 20.51
GSK's Net-margin (%) is ranked higher than
94% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. GSK: 20.51 )
GSK' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 20.51

5.76
23.94
ROE (%) 77.69
GSK's ROE (%) is ranked higher than
99% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.02 vs. GSK: 77.69 )
GSK' s 10-Year ROE (%) Range
Min: 18.39   Max: 173.51
Current: 77.69

18.39
173.51
ROA (%) 12.92
GSK's ROA (%) is ranked higher than
96% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.09 vs. GSK: 12.92 )
GSK' s 10-Year ROA (%) Range
Min: 3.87   Max: 27.12
Current: 12.92

3.87
27.12
ROC (Joel Greenblatt) (%) 79.22
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.47 vs. GSK: 79.22 )
GSK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.07   Max: 93.68
Current: 79.22

5.07
93.68
Revenue Growth (%) -0.90
GSK's Revenue Growth (%) is ranked higher than
60% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. GSK: -0.90 )
GSK' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 91
Current: -0.9

-1.5
91
EBITDA Growth (%) 17.30
GSK's EBITDA Growth (%) is ranked higher than
82% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. GSK: 17.30 )
GSK' s 10-Year EBITDA Growth (%) Range
Min: -11.8   Max: 85.9
Current: 17.3

-11.8
85.9
EPS Growth (%) 51.40
GSK's EPS Growth (%) is ranked higher than
94% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. GSK: 51.40 )
GSK' s 10-Year EPS Growth (%) Range
Min: -30.2   Max: 93.9
Current: 51.4

-30.2
93.9
» GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

GSK Guru Trades in Q3 2013

John Rogers 136,344 sh (+246.35%)
Jim Simons 3,891,300 sh (+186.65%)
Diamond Hill Capital 11,561 sh (+20.92%)
Murray Stahl 23,723 sh (+4.63%)
Manning & Napier Advisors, Inc 400,161 sh (+1.25%)
NWQ Managers 211,800 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
John Hussman 23,500 sh (unchged)
Tweedy Browne 151,030 sh (-0.04%)
Jeff Auxier 112,720 sh (-0.13%)
Ken Fisher 11,119,081 sh (-0.26%)
PRIMECAP Management 10,078,655 sh (-0.47%)
Dodge & Cox 61,290,600 sh (-1.04%)
Charles Brandes 1,896,714 sh (-1.82%)
Vanguard Health Care Fund 1,438,781 sh (-10.7%)
Steven Cohen 8,963 sh (-30%)
Warren Buffett 345,819 sh (-76.57%)
» More
Q4 2013

GSK Guru Trades in Q4 2013

Francis Chou 18,000 sh (New)
Joel Greenblatt 83,452 sh (New)
John Hussman 423,500 sh (+1702.13%)
John Rogers 421,201 sh (+208.93%)
Jim Simons 6,425,000 sh (+65.11%)
Charles Brandes 2,145,461 sh (+13.11%)
Ken Fisher 11,126,274 sh (+0.06%)
Jean-Marie Eveillard 1 sh (unchged)
Murray Stahl 23,723 sh (unchged)
Diamond Hill Capital 11,561 sh (unchged)
Warren Buffett Sold Out
Steven Cohen Sold Out
Jeff Auxier 112,170 sh (-0.49%)
Tweedy Browne 150,184 sh (-0.56%)
PRIMECAP Management 9,998,877 sh (-0.79%)
NWQ Managers 209,325 sh (-1.17%)
Dodge & Cox 60,479,650 sh (-1.32%)
Manning & Napier Advisors, Inc 383,698 sh (-4.11%)
Vanguard Health Care Fund 644,881 sh (-55.18%)
» More
Q1 2014

GSK Guru Trades in Q1 2014

Steven Cohen 5,921 sh (New)
Louis Moore Bacon 75,000 sh (New)
HOTCHKIS & WILEY 36,773 sh (New)
Bill Frels 4,496 sh (New)
Diamond Hill Capital 190,984 sh (+1551.97%)
John Rogers 662,150 sh (+57.21%)
Jim Simons 7,009,800 sh (+9.1%)
Charles Brandes 2,164,241 sh (+0.88%)
Ken Fisher 11,214,364 sh (+0.79%)
Murray Stahl 23,792 sh (+0.29%)
Joel Greenblatt 83,452 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
Francis Chou 18,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Dodge & Cox 60,386,550 sh (-0.15%)
Jeff Auxier 109,170 sh (-2.67%)
Tweedy Browne 142,598 sh (-5.05%)
PRIMECAP Management 9,177,877 sh (-8.21%)
Manning & Napier Advisors, Inc 329,053 sh (-14.24%)
John Hussman 323,500 sh (-23.61%)
NWQ Managers 148,800 sh (-28.91%)
» More
Q2 2014

GSK Guru Trades in Q2 2014

James Barrow 270,900 sh (New)
Pioneer Investments 93,226 sh (New)
HOTCHKIS & WILEY 4,949,118 sh (+13358.6%)
John Rogers 988,772 sh (+49.33%)
Jim Simons 8,869,400 sh (+26.53%)
Charles Brandes 2,500,048 sh (+15.52%)
Ken Fisher 11,365,903 sh (+1.35%)
Murray Stahl 23,992 sh (+0.84%)
Manning & Napier Advisors, Inc 331,544 sh (+0.76%)
Joel Greenblatt 83,528 sh (+0.09%)
NWQ Managers 148,850 sh (+0.03%)
Jean-Marie Eveillard 1 sh (unchged)
Francis Chou 18,000 sh (unchged)
John Hussman 323,500 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 60,226,050 sh (-0.27%)
Tweedy Browne 142,118 sh (-0.34%)
Jeff Auxier 108,620 sh (-0.5%)
Diamond Hill Capital 189,641 sh (-0.7%)
Bill Frels 3,846 sh (-14.46%)
PRIMECAP Management 5,156,449 sh (-43.82%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 Reduce -43.82%0.25%$51.55 - $56.39 $ 47.7-12%5156449
Charles Brandes 2014-06-30 Add 15.52%0.21%$51.55 - $56.39 $ 47.7-12%2500048
James Barrow 2014-06-30 New Buy0.02%$51.55 - $56.39 $ 47.7-12%270900
John Hussman 2014-03-31 Reduce -23.61%0.38%$50.9 - $56.66 $ 47.7-12%323500
Vanguard Health Care Fund 2014-03-31 Sold Out 0.11%$50.9 - $56.66 $ 47.7-12%0
John Hussman 2013-12-31 Add 1702.13%1.51%$49.31 - $53.68 $ 47.7-8%423500
Charles Brandes 2013-12-31 Add 13.11%0.16%$49.31 - $53.68 $ 47.7-8%2145461
Vanguard Health Care Fund 2013-12-31 Reduce -55.18%0.14%$49.31 - $53.68 $ 47.7-8%644881
Joel Greenblatt 2013-12-31 New Buy0.11%$49.31 - $53.68 $ 47.7-8%83452
Warren Buffett 2013-12-31 Sold Out 0.02%$49.31 - $53.68 $ 47.7-8%0
Warren Buffett 2013-09-30 Reduce -76.57%0.06%$50.27 - $52.96 $ 47.7-8%345819
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide